T. Rowe Price Investment Management, Inc. Macrogenics Inc Transaction History

T. Rowe Price Investment Management, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$9.77 - $21.47 $28.1 Million - $61.7 Million	-2,872,960 Reduced 50.94%	2,767,034 $40.7 Million
Q4 2023 Feb 14, 2024	BUY	$4.48 - $10.11 $663,228 - $1.5 Million	148,042 Added 2.7%	5,639,994 $54.3 Million
Q3 2023 Nov 14, 2023	BUY	$4.48 - $6.19 $131,264 - $181,367	29,300 Added 0.54%	5,491,952 $25.6 Million
Q2 2023 Aug 14, 2023	BUY	$4.62 - $7.54 $11.8 Million - $19.2 Million	2,549,247 Added 87.5%	5,462,652 $29.2 Million
Q1 2023 May 15, 2023	BUY	$4.82 - $7.24 $176,783 - $265,541	36,677 Added 1.27%	2,913,405 $20.9 Million
Q4 2022 Feb 14, 2023	SELL	$3.34 - $6.98 $17,638 - $36,861	-5,281 Reduced 0.18%	2,876,728 $19.3 Million
Q3 2022 Nov 14, 2022	BUY	$3.01 - $5.22 $8.67 Million - $15 Million	2,882,009 New	2,882,009 $9.97 Million

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of T. Rowe Price Investment Management, Inc., based on Form 13F filings with the SEC.

Stay updated on T. Rowe Price Investment Management, Inc. with notifications on news.